Sunesis Pharmaceuticals, Inc. (SNSS) financial statements (2021 and earlier)

Company profile

Business Address 395 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:29143243464339
Cash and cash equivalents1314278272215
Short-term investments16 535202124
Other undisclosed cash, cash equivalents, and short-term investments  00(0)00
Restricted cash and investments6      
Other undisclosed current assets2211111
Total current assets:36153343474440
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment0000000
Other noncurrent assets00    0
Other undisclosed noncurrent assets  1    
Total noncurrent assets:1010000
TOTAL ASSETS:37153443474441
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3356793
Accounts payable1122231
Accrued liabilities112233 
Employee-related liabilities1112222
Debt6773899
Derivative instruments and hedges, liabilities     48
Deferred revenue and credits 1238
Other undisclosed current liabilities1111236
Total current liabilities:9111311192834
Noncurrent Liabilities
Long-term debt and lease obligation0  11  9
Long-term debt, excluding current maturities   11  9
Operating lease, liability0
Liabilities, other than long-term debt0000134
Deferred revenue and credits  134
Other liabilities0000   
Total noncurrent liabilities:000111313
Total liabilities:10111322203047
Stockholders' equity
Stockholders' equity attributable to parent28422212714(6)
Preferred stock1221211916  
Common stock0000000
Additional paid in capital699642633600570536474
Accumulated other comprehensive income (loss)0 (0)(0)(0)(0)(0)
Accumulated deficit(683)(659)(633)(597)(559)(523)(480)
Total stockholders' equity:28422212714(6)
TOTAL LIABILITIES AND EQUITY:37153443474441

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:2013368
Operating expenses(25)(26)(35)(39)(42)(51)(40)
Operating loss:(23)(26)(34)(36)(39)(45)(32)
Nonoperating income
(Other Nonoperating income)
0000440
Interest and debt expense(1)(1)(1)(2)(1)(2)(3)
Net loss available to common stockholders, basic:(23)(27)(35)(38)(37)(43)(35)
Other undisclosed net loss available to common stockholders, diluted     (4) 
Net loss available to common stockholders, diluted:(23)(27)(35)(38)(37)(47)(35)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(23)(27)(35)(38)(37)(43)(35)
Comprehensive loss:(23)(27)(35)(38)(37)(43)(35)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent000(0)(0)(0)(0)
Comprehensive loss, net of tax, attributable to parent:(23)(27)(35)(38)(37)(43)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: